Fig. 4
Satb1 binds better under enhanced negative torsional stress and stabilizes BURs. a Satb1 ChIP-seq signal ratio of “MCF-10A + Satb1” cells treated with Topo I or II inhibitors, ICRF-193 (blue) and CPT (red), respectively, over untreated “MCF-10A + Satb1” cells, plotted against increasing raw ChIP-seq reads. The green line shows the ratio between two wild-type replicates. The logarithm plot of ratio shows increased Satb1 binding upon treatment. b Plot of ChIP-seq signal of ICRF-193 (blue), CPT (red) treated “MCF-10A + Satb1” cells versus motif density calculated from a 400 bp window centered on Satb1 binding sites. c Few representative examples of ChIP-seq peak intensity before treatment (lower panel) and after treatment with ICRF-193 (middle panel) and CPT (upper panel). d, e TMP-seq was performed on native MCF10A cells and cells expressing exogenous Satb1 in presence and absence of CPT and ICRF-193 respectively. Final TMP-seq signal was derived after correction for free genomic DNA-sequence bias at 50 bp resolution across a 4 kb window centered on Satb1 binding sites. Ratio of TMP-seq signals in “MCF-10A + Satb1” cells treated with CPT (d) or ICRF-193 (e) over untreated “MCF-10A + Satb1” cells. All error envelopes represent standard error of mean. Source data are provided as a Source Data file
